News | May 18, 2026
Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Nearly one in five women worldwide are now living with obesity
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
This is an exciting and meaningful milestone for GRIN Therapeutics
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Subscribe To Our Newsletter & Stay Updated
